Vericel

Vericel Corporation is a commercial-stage biopharmaceutical company based in Cambridge, Massachusetts, focused on developing and distributing cellular therapies for the sports medicine and severe burn care markets in the United States. The company offers two primary autologous cell therapy products: MACI, which is designed for repairing full-thickness cartilage defects in the knee, and Epicel, a skin replacement device intended for treating patients with deep-dermal or full-thickness burns. Vericel is also advancing ixmyelocel-T, a multicellular therapy that has completed Phase IIb clinical trials for advanced heart failure caused by dilated cardiomyopathy. Additionally, the company is working on NexoBrid, a biological orphan product aimed at the debridement of severe thermal burns, which is currently in the registration phase. Founded in 1989, Vericel was previously known as Aastrom Biosciences, Inc.